BYSI News and Press, BeyondSpring Inc.

FLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360...

Consistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Beyon...

In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC ...

2025-11-12 07:54:00 ET More on BeyondSpring BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript) Seeking Alpha’s Quant Rating on BeyondSpring Financial information for BeyondSpring Read the full article on Seeking Alpha For fu...

Two SITC 2025 presentations: First-in-class dendritic cell (DC) maturation agent Plinabulin drives immune re-sensitization in metastatic NSCLC patients who had progressed after PD-1/L1 inhibitors with disease control rate of 85% in combination with docetaxel and Keytruda. Mechanism studies with M...

2025-09-15 10:24:11 ET BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting Call September 15, 2025 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: BeyondSpring Inc. (BYSI) 2025 Annual Shareholders Meeting (Transcript)

2025-08-13 10:10:59 ET More on BeyondSpring Financial information for BeyondSpring Read the full article on Seeking Alpha For further details see: BeyondSpring GAAP EPS of -$0.10

ASCO 2025 presentation: First-in-class agent Plinabulin drives immune re-sensitization in NSCLC patients progressed to PD-1/L1 therapies Med (Cell Press) Publication with MD Anderson Collaboration highlights Plinabulin’s rapid dendritic cell activation in responding p...

Xenon Pharmaceuticals Inc. (XENE) is expected to report $-1.03 for Q2 2025 Gaia Inc. (GAIA) is expected to report $-0.08 for Q2 2025 Insight Molecular Diagnostics Inc. (IMDX) is expected to report for Q2 2025 Lightbridge Corporation (LTBR) is expected to report for Q2 2025 NewHold...

2025-08-10 18:45:14 ET BeyondSpring Inc. (BYSI) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 7.59%. The average open to low on the day of earnings was -4.02%. The average open to clos...